Tags

Type your tag names separated by a space and hit enter

A new era for monoclonal antibodies with applications in neurology (Review).
Exp Ther Med. 2021 Jan; 21(1):86.ET

Abstract

Medical research continues to focus on developing specific treatment strategies, including biological products that are effective and have a good safety profile. Due to their novelty, an updated overall view is offered on some neurological diseases which benefit from monoclonal antibodies (mAbs), for better treatment in clinical decisions. An extensive literature review was performed using PubMed with the following search terms: 'monoclonal antibodies' and 'history of monoclonal antibodies' and 'monoclonal antibodies in neurology'. The following information was collected: the era before the discoveries of mAbs, the stage of implementation of biotechnologies for mAbs, and the clinical trials submitted at https://clinicaltrials.gov/ with patients suffering from neurological diseases treated with mAbs. Since 2004, mAbs have been used to treat several neurological diseases, yielding new therapeutic perspectives: natalizumab, alemtuzumab and ocrelizumab for multiple sclerosis, eculizumab for myasthenia gravis, erenumab and frenazumab for migraine, galcanezumab for migraine and cluster headache, eculizumab for neuromyelitis optica spectrum disorder. As in other cases, drug repurposing is applied to monoclonal antibodies, saving time and money. These innovative therapies are more effective and can treat previously untreatable diseases. As better understanding of the pathogenic mechanisms of neurological diseases is gained, additional mAbs are expected to be developed at a lower cost and with better safety profile compared with current treatment options.

Authors+Show Affiliations

Department of Medical-Surgical and Prophylactic Disciplines, Faculty of Medicine, 'Titu Maiorescu' University, 031593 Bucharest, Romania. Department of Neurology, Faculty of Medicine, 'Ovidius' University of Constanta, 900470 Constanta, Romania.Department of Medical-Surgical and Prophylactic Disciplines, Faculty of Medicine, 'Titu Maiorescu' University, 031593 Bucharest, Romania.Department of Neurology, Faculty of Medicine, 'Ovidius' University of Constanta, 900470 Constanta, Romania. Department of Neurology, 'St. Apostol Andrei' Clinical Emergency Hospital, 900591 Constanta, Romania.Department of Endocrinology, 'C.I. Parhon' National Institute of Endocrinology, 011863 Bucharest, Romania.Department of Medical-Surgical and Prophylactic Disciplines, Faculty of Medicine, 'Titu Maiorescu' University, 031593 Bucharest, Romania. Department of Gastroenterology, 'Carol Davila' Central Military Emergency University Hospital, 010242 Bucharest, Romania.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33363597

Citation

Sirbu, Carmen Adella, et al. "A New Era for Monoclonal Antibodies With Applications in Neurology (Review)." Experimental and Therapeutic Medicine, vol. 21, no. 1, 2021, p. 86.
Sirbu CA, Ghinescu MC, Axelerad AD, et al. A new era for monoclonal antibodies with applications in neurology (Review). Exp Ther Med. 2021;21(1):86.
Sirbu, C. A., Ghinescu, M. C., Axelerad, A. D., Sirbu, A. M., & Ionita-Radu, F. (2021). A new era for monoclonal antibodies with applications in neurology (Review). Experimental and Therapeutic Medicine, 21(1), 86. https://doi.org/10.3892/etm.2020.9519
Sirbu CA, et al. A New Era for Monoclonal Antibodies With Applications in Neurology (Review). Exp Ther Med. 2021;21(1):86. PubMed PMID: 33363597.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A new era for monoclonal antibodies with applications in neurology (Review). AU - Sirbu,Carmen Adella, AU - Ghinescu,Minerva Claudia, AU - Axelerad,Any Docu, AU - Sirbu,Anca Maria, AU - Ionita-Radu,Florentina, Y1 - 2020/11/26/ PY - 2020/06/03/received PY - 2020/07/03/accepted PY - 2020/12/28/entrez PY - 2020/12/29/pubmed PY - 2020/12/29/medline KW - cluster headache KW - migraine KW - monoclonal antibodies KW - multiple sclerosis KW - myasthenia gravis KW - neuromyelitis optica spectrum disorders SP - 86 EP - 86 JF - Experimental and therapeutic medicine JO - Exp Ther Med VL - 21 IS - 1 N2 - Medical research continues to focus on developing specific treatment strategies, including biological products that are effective and have a good safety profile. Due to their novelty, an updated overall view is offered on some neurological diseases which benefit from monoclonal antibodies (mAbs), for better treatment in clinical decisions. An extensive literature review was performed using PubMed with the following search terms: 'monoclonal antibodies' and 'history of monoclonal antibodies' and 'monoclonal antibodies in neurology'. The following information was collected: the era before the discoveries of mAbs, the stage of implementation of biotechnologies for mAbs, and the clinical trials submitted at https://clinicaltrials.gov/ with patients suffering from neurological diseases treated with mAbs. Since 2004, mAbs have been used to treat several neurological diseases, yielding new therapeutic perspectives: natalizumab, alemtuzumab and ocrelizumab for multiple sclerosis, eculizumab for myasthenia gravis, erenumab and frenazumab for migraine, galcanezumab for migraine and cluster headache, eculizumab for neuromyelitis optica spectrum disorder. As in other cases, drug repurposing is applied to monoclonal antibodies, saving time and money. These innovative therapies are more effective and can treat previously untreatable diseases. As better understanding of the pathogenic mechanisms of neurological diseases is gained, additional mAbs are expected to be developed at a lower cost and with better safety profile compared with current treatment options. SN - 1792-0981 UR - https://www.unboundmedicine.com/medline/citation/33363597/A_new_era_for_monoclonal_antibodies_with_applications_in_neurology__Review__ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/33363597/ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.